Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals

Recombinant manufacturing

Recombinant manufacturing

Coagulation factor replacement therapy products are either plasma-based or recombinant—made without human blood, plasma or proteins. Compared to plasma-based treatments, recombinant manufacturing minimizes the risk of blood-borne pathogens.1

Our manufacturing process

Novo Nordisk manufactures only recombinant factor products, which are produced in cell lines engineered to include the gene for human clotting factors. These cell lines are considered to be free of viruses.2

Recombinant factor products undergo multiple steps to ensure safety and purity2

Cell bank icon

Step 1

Cell Bank: Cells are created that produce clotting factor identical or similar to the one that occurs naturally in the human body

Production icon

Step 2

Production: The clotting factor is made by cells grown under careful lab conditions

Purification icon

Step 3

Purification: A cleansing process removes any remaining impurities

Freeze icon

Step 4

Preparation: The factor is freeze-dried and prepared for long-term storage and use as needed

Inspection icon

Step 5

Quality control: A final inspection ensures a high quality product

MASAC recommendations

The National Hemophilia Foundation’s Medical and Scientific Advisory Council (MASAC) issues expert recommendations, statements, and advisories on treatment and care of bleeding disorders.

Guidelines for bleeding disorders

Access MASAC recommendations to determine when recombinant products are recommended for the management of bleeding disorders.

Find out more

Actor portrayal

References:

  1. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.
  2. Pipe SW. Recombinant clotting factors. Thromb Haemost. 2008;99(5):840-850.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2021 Novo Nordisk All rights reserved.  US21HCP00067 October 2021

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials